Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 751 to 760 of 1090 total matches.
Roxybond - An Abuse-Deterrent Formulation of Short-Acting Oxycodone
The Medical Letter on Drugs and Therapeutics • Sep 10, 2018 (Issue 1555)
with chronic use.
DRUG INTERACTIONS — Oxycodone is metabolized by
CYP3A4 and CYP2D6. Concurrent ...
The FDA has approved Roxybond (Daiichi Sankyo), an
short-acting (SA) oxycodone formulation with
abuse-deterrent properties, for treatment of pain
requiring management with an opioid. Roxybond
is the first SA opioid to be approved as an abuse-deterrent
product. Oxaydo, another IR oxycodone
formulation, has properties that discourage its
intranasal and intravenous use, but is not considered
an abuse-deterrent product by the FDA. Use of
opioids for treatment of pain was reviewed in a
recent issue.
Ziprasidone (Geodon) For Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jun 11, 2001 (Issue 1106)
has not caused agranulocytosis.
DRUG INTERACTIONS — Ziprasidone should not be used with other drugs that prolong ...
Ziprasidone (Geodon - Pfizer), a benzisothiazolyl piperazine, has been approved by the FDA for oral treatment of schizophrenia. An intramuscular formulation will probably be available in the near future.
Tegaserod Maleate (Zelnorm) for IBS with Constipation
The Medical Letter on Drugs and Therapeutics • Sep 16, 2002 (Issue 1139)
drug interactions have been reported.
DOSAGE AND COST — Zelnorm is available in 2-mg and 6-mg tablets ...
Tegaserod maleate (teg a ser' od; Zelnorm - Novartis), a serotonin derivative, has received FDA approval for short-term treatment of women with irritable bowel syndrome (IBS) whose primary symptom is constipation. Alosetron (Lotronex), which was withdrawn previously because of toxicity, will soon be available again for women with severe diarrhea-predominant IBS (Medical Letter 2002; 44:67).
Revefenacin (Yupelri) for COPD
The Medical Letter on Drugs and Therapeutics • Jan 28, 2019 (Issue 1564)
with tiotropium
(≤0.9% vs 2.8%).4
DRUG INTERACTIONS — Use of revefenacin with
OATP1B1 and OATP1B3 inhibitors ...
The FDA has approved revefenacin (Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic
agent (LAMA) administered once daily by standard
jet nebulizer, for maintenance treatment of chronic
obstructive pulmonary disease (COPD). Revefenacin
is the second nebulized LAMA to be approved for this
indication; glycopyrrolate (Lonhala Magnair), which
is administered twice daily with a portable handheld
nebulizer, was the first.
Pegvisomant (Somavert) for Acromegaly
The Medical Letter on Drugs and Therapeutics • Jul 07, 2003 (Issue 1160)
with use of pegvisomant could have long-term adverse effects is not known.
DRUG INTERACTIONS — According ...
The FDA has approved pegvisomant (Somavert Pfizer), a growth hormone receptor antagonist, for parenteral treatment of acromegaly in patients who are not candidates for or have had an inadequate response to surgery or other treatment. This review describes the disease of acromegaly and its standard treatment options. Also included are sections on the mechanism of action, pharmacokinetics, adverse effects, drug interactions, and the dosage and cost of pegvisomant. Results of clinical studies are discussed. The conclusion provides an overall assessment of the prospects for this new drug.
Extended-Release Hydrocodone (Zohydro ER) for Pain
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014 (Issue 1444)
The Medical Letter®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 145 ...
The FDA has approved an extended-release oral formulation
of the opioid agonist hydrocodone (Zohydro ER –
Zogenix) for management of pain severe enough to
require continuous, long-term therapy and for which
alternative treatment options are inadequate. Zohydro ER
is the first single-ingredient hydrocodone product to be
marketed in the US. Hydrocodone has been available for
years in combination with acetaminophen (Vicodin, and
others) or ibuprofen (Vicoprofen, and others).
Brivaracetam (Briviact) for Epilepsy
The Medical Letter on Drugs and Therapeutics • Jul 18, 2016 (Issue 1499)
:e46.
DRUG INTERACTIONS — Coadministration with rifampin
decreased plasma concentrations ...
Brivaracetam (Briviact – UCB), an analog of
levetiracetam (Keppra, and others), has been approved
by the FDA for adjunctive treatment of partial-onset
seizures in patients ≥16 years old. New drugs for
epilepsy are often approved initially only as adjunctive
treatment for partial seizures.
Ripretinib (Qinlock) for GIST (online only)
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
the last dose.
DRUG INTERACTIONS – Ripretinib is metabolized
primarily by CYP3A4 and to a lesser extent ...
The FDA has approved the oral tyrosine kinase inhibitor
ripretinib (Qinlock – Deciphera) for treatment of adults
with advanced gastrointestinal stromal tumors (GISTs)
who have previously received treatment with ≥3 kinase
inhibitors, including imatinib (Gleevec, and generics).
DaxibotulinumtoxinA (Daxxify) for Frown Lines (online only)
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024 (Issue 1707)
INTERACTIONS — Botulinum toxin products should not be given with other drugs that interfere with neuromuscular ...
The FDA has approved daxibotulinumtoxinA-lanm
(Daxxify – Revance), an acetylcholine release inhibitor
and neuromuscular blocking agent, for temporary
improvement in the appearance of moderate to severe
glabellar (frown) lines associated with corrugator
and/or procerus muscle activity. Daxxify is the fifth
botulinumtoxin type A product to be approved in the
US for this indication (see Table 1). It is also approved
for treatment of cervical dystonia in adults
Med Lett Drugs Ther. 2024 Jul 22;66(1707):e121-2 doi:10.58347/tml.2024.1707g | Show Introduction Hide Introduction
Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
of endometrial malignancy were reported with use
of the drug in clinical trials.6
DRUG INTERACTIONS ...
Fezolinetant (Veozah – Astellas), a first-in-class
neurokinin 3 (NK3) receptor antagonist, has been
approved by the FDA for treatment of moderate to
severe vasomotor symptoms (VMS) due to menopause.
It is the second nonhormonal treatment to be approved
in the US for this indication; a low-dose formulation of
the selective serotonin reuptake inhibitor (SSRI)
paroxetine mesylate (Brisdelle) was approved in 2013.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):97-9 doi:10.58347/tml.2023.1679a | Show Introduction Hide Introduction